Printer Friendly

SOCAL CAPITAL ANNOUNCES UPDATE ON RESULTS OF PHASE-ONE EXTERNAL CLINICAL EVALUATION TRIALS ON HIV-1 DIAGNOSTIC ASSAY

 VANCOUVER, British Columbia, Feb. 9 /PRNewswire/ -- Socal Capital Corp. (Vancouver: SOL) today announced an update on the results from the phase-one external clinical evaluation trials conducted at a leading academic medical facility in San Francisco on its proprietary HIV-1 diagnostic assay.
 The phase-one test results, first reported by the company in a Jan. 21, 1993 news release, showed 100 percent sensitivity and 96.7 percent specificity.
 Those results were subjected to Western Blot confirmation assay, the standard accepted by the diagnostics industry. The results confirm that the EDI HIV-1 diagnostic assay indeed discovered positives among a presumed negative panel, thereby establishing the EDI assay to be 100 percent specific. The company is extremely encouraged with these results.
 Socal Capital Corp., through EDI's manufacturing/laboratory facility, is committed to the delivery of an in-expensive, easy-to- use, rapid diagnostic system for HIV type-1 which utilizes whole blood. EDI's revolutionary technology can be manufactured for less than US$0.20 per test-kit. Other equivalent rapid diagnostic technology currently sells for as much as US$9.00 per test kit.
 This technology represents the leading edge of the diagnostics industry in that it reduces the cost dramatically while maintaining extremely reliable and accurate results. This has enabled EDI to focus on developing countries where the pandemic is at its worst. EDI management has travelled extensively throughout the world and is currently negotiating joint venture/licensing agreements with individuals located in India, China, Singapore, Malaysia, Mexico and Russia.
 The EDI technology has received considerable media attention worldwide and was recently featured at the International AIDS Conference in Cameroon, West Africa and has also attracted the attention of such organizations as STOP-AIDS-WORLDWIDE.
 For further information on Socal Capital Corp. or its California subsidiary, Empyrean Diagnostics Inc., contact Daniel Bland at 604-687-6223 or 800-567-8181.
 -0- 2/9/93
 /CONTACT: Daniel Bland of Socal Capital, 604-687-6223 or 800-567-8181/
 (SOL.)


CO: Socal Capital Corp. ST: British Columbia IN: HEA MTC SU:

LS -- LA035 -- 4903 02/09/93 18:34 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Feb 9, 1993
Words:331
Previous Article:STATEMENT BY GENERAL DIRECTOR OF JAMA WASHINGTON
Next Article:DATA RACE PRESIDENT COMMENTS ON STOCK PRICE ACTIVITY
Topics:


Related Articles
EMPYREAN DIAGNOSTICS INC., SUBSIDIARY OF SOCAL CAPITAL CORP., ANNOUNCES RESULTS FROM PHASE-2 CLINICAL TRIALS
EMPYREAN DIAGNOSTICS INC. (SUBSIDIARY OF SOCAL CAPITAL CORP.) ENTERS FORMAL LETTER AGREEMENT
SOCAL CAPITAL CORP. ANNOUNCES RESULTS OF CLINICAL TRIALS
SOCAL CAPITAL CORP. ANNOUNCES NAME CHANGE
AMPLICOR HIV-1 MONITOR(TM) TEST FIRST TO RECEIVE FDA APPROVAL FOR MARKETING
Gen-Probe Announces Results From the Initial Field Evaluation of The TIGRIS(TM) Instrument System for Clinical Diagnostic Testing.
Clinical Trials of Procleix(R) Ultrio(TM) Assay Begin on Procleix TIGRIS(R) System.
Clinical Trials Begin for Procleix(R) Ultrio(TM) Assay; Innovative Molecular Test Further Safeguards Blood Supply by Detecting Hepatitis B in...
Calypte Biomedical Presents Results of Its Rapid HIV-1/2 Field Trial Tests at the XV International AIDS Conference in Bangkok.
Calypte's Aware(TM) HIV-1/2 BSP Test Receives Zimbabwe Approval.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters